证券日报网讯 1月22日，联环药业发布公告称，公司近日获国家药监局核准签发茚达特罗莫米松吸入粉 雾剂（II）《药物临床试验批准通知书》，同意开展用于成人和12岁及以上青少年哮喘维持治疗的临床 试验，项目累计研发投入2213.57万元。 （文章来源：证券日报） ...

Group 1 - The company, West Point Pharmaceutical, announced a plan to repurchase its issued A-shares using self-owned and/or self-raised funds through centralized bidding [2] - The total amount for the repurchase is set to be no less than RMB 25 million and no more than RMB 50 million [2] - The repurchase price will not exceed RMB 42.00 per share [2] - The implementation period for the repurchase is within 12 months from the date the board of directors approves the plan [2]

Core Viewpoint - As of January 22, 2026, the disclosure rate of active equity funds' quarterly reports reached 100%, with a slight decrease in overall positions but remaining at historically high levels [2][3] Fund Positioning - Active equity funds' positions decreased by 0.83 percentage points to 86.6%, still the second highest level after Q3 2025, with ordinary stock, mixed equity, and flexible allocation funds decreasing by 0.5, 0.8, and 0.9 percentage points respectively [3] - The ChiNext board saw an increase in positions by 1.2 percentage points to 25.0%, while the Sci-Tech Innovation board decreased by 0.9 percentage points to 16.6%, and the main board decreased by 0.3 percentage points to 58.2% [3] Sector Allocation - The sectors with the highest increases in positions were non-ferrous metals (+2.3 percentage points), communication (+1.9 percentage points), and non-bank financials (+0.9 percentage points), with non-ferrous metals increasing for four consecutive quarters and communication for three [3] - The sectors with the largest decreases were electronics (-1.7 percentage points), pharmaceuticals and biology (-1.5 percentage points), and media (-1.2 percentage points) [3] Sub-sector Insights - In the secondary industry, the sectors with the highest increases were communication equipment (+1.9 percentage points), industrial metals (+1.2 percentage points), and insurance (+0.9 percentage points), while the largest decreases were in consumer electronics (-1.9 percentage points), batteries (-1.3 percentage points), and chemical pharmaceuticals (-1.0 percentage points) [3] Stock Performance - The stocks with the highest increases in positions included Zhongji Xuchuang, Xinyi Technology, Dongshan Precision, China Ping An, and Zijin Mining, while the stocks with the largest decreases included Industrial Fulian, Yiwei Lithium Energy, CATL, Luxshare Precision, and Focus Media [3] Hong Kong Market Overview - In the Hong Kong market, the active equity positions decreased by 3.1 percentage points to 16.0%, with increases in financials, materials, and energy sectors, while decreases were seen in non-essential consumer, information technology, and healthcare sectors [3] - The most increased stocks were China Ping An H, CNOOC H, and China Life H, while the most decreased stocks were Alibaba, Tencent Holdings, and SMIC [3]

（文章来源：证券日报） 本报讯 1月22日晚间，重庆博腾制药科技股份有限公司（以下简称"博腾股份"）发布2025年度业绩预 告，预计归属于上市公司股东的净利润为8000万元至10500万元，同比扭亏为盈。 2025年度，公司坚定围绕"收入恢复增长，逐步实现扭亏为盈"的经营目标，持续加强业务拓展，提升经 营大盘系统管理水平。公告显示，报告期内，公司预计实现营业收入33.5亿元至35亿元，同比增长11% 至16%，收入增长主要由临床三期至商业化阶段的项目需求驱动。盈利增长主要得益于营业收入增长带 来的规模效应、降本增效和精益运营提升毛利率、费用稳中有降等。此外，随着公司业务恢复增长，公 司资产的使用效率逐步提升，基于初步减值测试，公司本期资产减值损失预计将同比大幅减少。 ...

西点药业（301130）(301130.SZ)公告，公司拟回购公司股份用于实施员工持股计划或股权激励。回购 股份的资金总额不低于2500万元(含)，不超过5000万元(含)。回购股份的价格不超过42.00元/股(含)。回 购股份的实施期限自公司董事会审议通过本次回购股份方案之日起12个月内 ...

Group 1 - The company, Boten Co., Ltd. (300363.SZ), has disclosed its annual performance forecast for 2025, expecting a net profit attributable to shareholders of between 80 million and 105 million yuan, indicating a turnaround from losses to profits [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is anticipated to be between 48 million and 70 million yuan [1]

博腾股份（300363）(300363.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利润 8000万元至1.05亿元，扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润4800万元至7000万 元。 ...

Core Viewpoint - The company announced a delay in the completion of its "Escitalopram Oxalate API Production Project" due to construction challenges, but this will not materially affect its main business or fundraising plans [1] Group 1: Project Investment and Funding - The company plans to invest 53.50 million yuan in the production project, funded by proceeds from its initial public offering [1] - The project aims to enhance the production capacity of active pharmaceutical ingredients [1] Group 2: Project Delay and Impact - The timeline for the project’s operational status has been postponed from February 23, 2026, to June 30, 2026, due to existing infrastructure issues affecting construction [1] - The delay does not involve changes to the project’s implementation entity, construction content, investment scale, or funding usage [1] - The company emphasizes that the delay will not impact its overall strategic goals and aims to improve the efficiency of fundraising utilization [1] Group 3: Project Management - The company will continue to strengthen project management to ensure timely completion of the construction [1]

1月22日，一品红收跌1.34%，收盘价为35.31元，发生1笔大宗交易，合计成交量11.88万股，成交金额 419.48万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第1笔成交价格为35.31元，成交11.88万股，成交金额419.48万元，溢价率为0.00%，买方营业部为机构 专用，卖方营业部为中信证券股份有限公司上海分公司。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为419.48万元。该股近5个交易日累 计下跌9.14%，主力资金合计净流出8981.29万元。 ...

南财智讯1月22日电，西点药业公告，公司于2026年1月22日召开第八届董事会第十四次会议，审议通过 了相关议案，同意使用额度不超过0.75亿元的暂时闲置募集资金（含超募资金）进行现金管理，投资安 全性高、流动性好、期限不超过12个月的保本型投资产品。使用期限自董事会审议通过之日起12个月内 有效，资金在额度范围内可滚动使用。该事项不会影响募集资金投资项目进度和公司正常生产经营。 ...